News
Dr. Maria Molina is appointed new scientific director of the Respiratory Diseases Area of the CIBER
This is a relevant position, endorsed by the scientific and care trajectory of Dr. Maria Molina, head of the Pneumology research group of the Institute of Bellvitge Biomedical Research.
Ten migraine days less each month in patients over 65, thanks to new anti-CGRP monoclonal antibodies
The results of the study led by IDIBELL and the Hospital de Bellvitge solve a pending issue and open new ways to improve the patients’ life quality with safe and effective treatment.
Dr. Riera-Mestre, elected editor of the most prestigious journal in the field of minority diseases
The coordinator of the IDIBELL Systemic, Vascular and Aging Diseases group will be globally responsible, together with two other editors, for the section on Rare Cardiovascular Diseases of the Orphanet Journal of Rare Diseases.
The Catalan Institute of Oncology and IDIBELL lead the PIECES Project aimed at implementing interventions in the field of cancer prevention
Funded by the European Union, the project aims to develop, evaluate and disseminate a methodological implementation framework for cancer known as the ‘Integrated Implementation Kit’ in six risk factors, such as tobacco, alcohol, ‘sun exposure, the human papilloma virus, nutrition and physical activity.
A new endoscopy study from Bellvitge published in the main scientific journal of the digestive specialty
The American Journal of Gastrointestinal Endoscopy published a multicenter study on the treatment of gastrointestinal subepithelial tumors led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Digestive Endoscopy Unit of the Bellvitge University Hospital (HUB).
Small RNAs in semen are useful biomarkers to determine the origin of azoospermia
The objective was to select non-invasive biomarkers with diagnostic and prognostic utility, which allow the identification of individuals with a real possibility of recovering sperm from a testicular biopsy, necessary for assisted reproduction treatment.
The omic sciences to advance in precision medicine are the focus of the NeuroDebate 2023 conference
This past June 9 and 10, NeuroDebate took place, a conference promoted by the Bellvitge University Hospital (HUB), the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona.
A new study seeks solutions to minimize complications in heart transplants
The Bioheart group has carried out a retrospective analysis of 2,376 heart transplants performed in 14 hospitals throughout the country and has concluded that the choice between peripheral or central cannulation for ECMO-Venoarterial placement determines an improvement in survival.
A new paradigm in the treatment of patients with diffuse large B-cell lymphoma, one of the most aggressive blood cancers
It is the first treatment in the last 30 years that represents a relative improvement of 38% in the overall survival of patients compared to standard treatment. The results of Phase III study ZUMA-7 show that this new treatment with Yescarta (axicabtagén ciloleucel, known as axicel) reduces the risk of death by 27.4%.